Section 106: Gene Therapy Vectors in CBS/PSP

therapeutic

Section 106: Gene Therapy Vectors in CBS/PSP

Overview

<table class=“infobox infobox-therapeutic”> <tr> <th class=“infobox-header” colspan=“2”>Section 106: Gene Therapy Vectors in CBS/PSP</th> </tr> <tr> <td class=“label”>Serotype</td> <td>Primary Receptor</td> </tr> <tr> <td class=“label”>AAV9</td> <td>N-linked galactose</td> </tr> <tr> <td class=“label”>AAVrh.10</td> <td>Unknown</td> </tr> <tr> <td class=“label”>AAV5</td> <td>N-linked sialic acid</td> </tr> <tr> <td class=“label”>AAV8</td> <td>Unknown</td> </tr> <tr> <td class=“label”>AAV-PHP.B</td> <td>Unknown</td> </tr> <tr> <td class=“label”>AAV-PHP.eB</td> <td>Unknown</td> </tr> <tr> <td class=“label”>Program</td> <td>Vector</td> </tr> <tr> <td class=“label”>BIIB080 (IONIS-MAPTRx)</td> <td>ASO (not AAV)</td> </tr> <tr> <td class=“label”>AAV-GDNF</td> <td>AAV2</td> </tr> <tr> <td class=“label”>AAV-NTN</td> <td>AAV2</td> </tr> <tr> <td class=“label”>VY-AADC01</td> <td>AAV2</td> </tr> </table>

Gene therapy represents one of the most promising disease-modifying approaches for neurodegenerative tauopathies, including corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These 4R-tauopathies are characterized by abnormal tau protein aggregation, neuroinflammation, and progressive neuronal dysfunction leading to movement disorders, cognitive decline, and eventual disability[@boxer2020]. Traditional small-molecule approaches have shown limited efficacy in halting disease progression, driving significant interest in gene therapy strategies that can target the underlying pathological mechanisms.

Gene therapy vectors enable precise delivery of therapeutic genetic material to specific brain regions and cell types, offering several advantages over conventional pharmacological approaches. By delivering genes encoding therapeutic proteins, regulatory RNAs, or gene-editing components directly to affected neurons and glia, gene therapy can achieve sustained protein expression, tissue-specific targeting, and modulation of disease pathways that are otherwise difficult to address with systemically administered drugs[@hudry2018].

This section comprehensively reviews the current landscape of gene therapy vectors for CBS and PSP, focusing on adeno-associated virus (AAV) and lentiviral platforms, delivery methodologies, therapeutic target genes, and the status of clinical development. The unique challenges of treating tauopathies with gene therapy—including the need to address both neuronal and glial pathology, achieve adequate brain penetration, and target multiple disease mechanisms—are examined in detail.

1. Gene Therapy Platforms for CNS Disorders

1.1 Comparison of Vector Platforms

Multiple viral vector platforms have been developed for gene delivery to the central nervous system, each with distinct advantages and limitations. The choice of vector platform significantly impacts therapeutic outcomes, safety profile, and clinical applicability.

flowchart TD
    A["Gene Therapy Vectors for CNS"]  -->  B["AAV Vectors"]
    A  -->  C["Lentiviral Vectors"]
    A  -->  D["Adenoviral Vectors"]
    A  -->  E["Non-viral Methods"]

    B  -->  B1["Advantages"]
    B  -->  B2["Limitations"]
    C  -->  C1["Advantages"]
    C  -->  C2["Limitations"]

    B1  -->  B1a["Non-pathogenic<br/>Long-term expression<br/>Low immunogenicity<br/>BBB crossing (certain serotypes)"]
    B1a  -->  F1["4.7 kb capacity<br/>Pre-existing immunity<br/>Dose-dependent toxicity"]

    C1  -->  C1a["Larger capacity<br/>Integration capability<br/>High transduction efficiency"]
    C1a  -->  F2["Insertional mutagenesis<br/>Higher immunogenicity<br/>Transient expression (non-integrating)"]

    style B1a fill:#0e2e10,stroke:#333
    style C1a fill:#0e2e10,stroke:#333
    style F1 fill:#3b1114,stroke:#333
    style F2 fill:#3b1114,stroke:#333

AAV Vectors have emerged as the dominant platform for CNS gene therapy due to their favorable safety profile and natural ability to cross the blood-brain barrier (BBB) with certain serotypes. AAV is a small, non-pathogenic parvovirus that does not integrate into the host genome but maintains episomal DNA, providing long-term expression without the risk of insertional mutagenesis[“@wang2019”]. Multiple FDA-approved AAV-based gene therapies demonstrate clinical viability, including Luxturna (RPE65 mutation) and Zolgensma (spinal muscular atrophy).

Lentiviral Vectors are derived from HIV and offer a larger packaging capacity (~8 kb), enabling delivery of larger transgene cassettes including multiple genes or larger regulatory elements. Lentiviral vectors can integrate into the host genome, providing permanent expression, but this integration carries theoretical risks of insertional mutagenesis. Non-integrating lentiviral variants have been developed to improve safety while maintaining high transduction efficiency[“@delenda2019”].

Adenoviral Vectors provide high transduction efficiency but trigger strong immune responses, limiting repeat dosing. They are less commonly used for neurodegenerative applications but may have utility for short-term expression needs.

1.2 Vector Design Considerations for Tauopathies

Gene therapy for CBS and PSP requires careful vector design to address the specific pathological features of these tauopathies:

Cell-Type Targeting: Both neurons and glia contribute to tau pathology propagation. Effective therapy may require targeting multiple cell types, either through native vector tropism or engineering of cell-specific promoters. Neuronal transduction using synapsin or CaMKII promoters, or astrocyte targeting using GFAP promoters, enables cell-type-specific expression[@gray2011].

Expression Level Control: Therapeutic gene expression must be carefully controlled—insufficient expression may provide no benefit, while excessive expression could cause toxicity. Self-regulating expression systems using inducible promoters or feedback mechanisms can provide dynamic control.

Therapeutic Payload Size: The limited packaging capacity of AAV (~4.7 kb) constrains the size of therapeutic transgenes. Larger genes or multiple genes require alternative vectors or split-intein systems.

2. AAV Vector Biology and Serotypes

2.1 AAV Structure and Biology

Adeno-associated viruses are small, non-enveloped particles approximately 25 nm in diameter containing a single-stranded DNA genome. The viral genome encodes only rep (replication) and cap (capsid) genes required for viral replication, making the vectors inherently replication-deficient when the viral genes are replaced with therapeutic transgenes[@muzyczka2022].

The AAV lifecycle involves binding to cell surface receptors, internalization via endocytosis, endosomal escape, trafficking to the nucleus, and conversion of the single-stranded genome to double-stranded DNA. This process limits expression onset to days or weeks post-administration, which is acceptable for most therapeutic applications.

Serotype Diversity: Multiple natural AAV serotypes exist, each with distinct capsid proteins determining receptor binding, tissue tropism, and immunogenicity. For CNS applications, specific serotypes have demonstrated superior brain penetration and neuronal transduction.

2.2 AAV Serotypes for CBS/PSP

The choice of serotype significantly impacts therapeutic outcomes. AAV9 has emerged as the preferred serotype for neurodegenerative applications due to its demonstrated ability to cross the BBB and achieve widespread neuronal transduction throughout the brain and spinal cord[@duque2009]. Clinical data from Zolgensma (AAV9-mediated SMN1 delivery) confirms the safety and efficacy of this approach in pediatric patients.

flowchart TD
    A["AAV Vector Administration"]  -->  B["Systemic Delivery<br/>IV Injection"]

    B  -->  C{"Serotype Properties"}
    C  -->|"AAV9"| D["Natural BBB Transcytosis"]
    C  -->|"AAVrh.10"| E["Moderate BBB Crossing"]
    C  -->|"PHP variants"| F["Engineered Enhanced Crossing"]

    D  -->  G["Broad CNS Distribution"]
    E  -->  G
    F  -->  G

    G  -->  H["Neuronal Transduction"]
    G  -->  I["Astrocyte Transduction"]
    G  -->  J["Microglial Transduction"]

    H  -->  K["Therapeutic Gene Expression"]
    I  -->  K
    J  -->  K

    K  -->  L["Tau Pathology Modulation<br/>Neuroprotection<br/>Inflammation Reduction"]

    style C fill:#3a3000,stroke:#333
    style G fill:#0a1929,stroke:#333
    style K fill:#0e2e10,stroke:#333

2.3 Engineered AAV Capsids

Rational engineering and directed evolution have produced AAV variants with enhanced CNS targeting properties. The PHP (phosphorus-helix) family of capsids, developed through in vivo selection in mice, demonstrates dramatically improved BBB crossing compared to natural serotypes[@deverman2016].

PHP.B and PHP.eB variants achieve up to 10-fold higher transduction in the mouse CNS following intravenous administration. These capsids interact with Ly6a (SCA-2) receptors on brain endothelial cells, facilitating transcytosis. However, the human ortholog (LY6E) shows different binding characteristics, requiring validation of cross-species relevance.

AAV-DJ and related variants from directed evolution demonstrate broad tropism and reduced recognition by neutralizing antibodies, potentially enabling treatment of patients with pre-existing anti-AAV immunity.

3. Lentiviral Vectors for CBS/PSP

3.1 Lentiviral Vector Design

Lentiviral vectors are derived from HIV-1 and provide a larger packaging capacity than AAV, enabling delivery of larger therapeutic payloads including multiple transgenes, longer promoters, or gene-editing components. Modern lentiviral vectors have been significantly de-risked through the removal of essential viral genes and development of self-inactivating designs[@sakuma2012].

Integrating vs. Non-Integrating: Traditional lentiviral vectors integrate into the host genome, providing permanent transgene expression. Non-integrating variants maintain high transduction efficiency while avoiding integration-related risks, offering a safer profile for neurological applications.

Envelope Proteins: Vesicular stomatitis virus G-glycoprotein (VSV-G) pseudotyping is standard for lentiviral vectors, enabling broad tropism including neurons and glia. Alternative envelopes can be selected for enhanced CNS targeting.

3.2 Advantages for Tauopathies

Lentiviral vectors offer specific advantages for CBS/PSP gene therapy:

Packaging Capacity: The ~8 kb capacity enables delivery of larger genes (e.g., full-length MAPT, larger promoter elements) and multiple therapeutic genes in a single vector. This is particularly relevant for tau-focused approaches requiring modulation of multiple pathway components.

High Transduction Efficiency: Lentiviral vectors achieve high MOI-independent transduction, ensuring therapeutic expression in a high percentage of target cells with lower vector doses.

Sustained Expression: Integrated or episomal lentiviral genomes provide long-term expression without the need for re-administration, important for progressive neurodegenerative diseases.

3.3 Clinical Considerations

While lentiviral vectors have been successfully used in CNS clinical trials (including for Parkinson’s disease), they face challenges in the CBS/PSP context:

  • Immunogenicity: Lentiviral vectors elicit stronger immune responses than AAV, potentially limiting repeat dosing
  • Manufacturing Complexity: Lentiviral production is more complex and expensive than AAV
  • Safety Concerns: Although modern designs minimize insertional mutagenesis risk, integration remains a theoretical concern

4. Delivery Methods to the CNS

4.1 Systemic (Intravenous) Delivery

Intravenous administration offers the least invasive route for CNS gene therapy but requires vectors capable of crossing the BBB. AAV9 and engineered variants like PHP.B demonstrate natural or enhanced transcytosis across brain endothelial cells[@foust2013].

Advantages:

  • Non-invasive, amenable to repeat dosing
  • Widespread CNS distribution
  • Established clinical precedent (Zolgensma)

Limitations:

  • Requires high vector doses (10^14-10^15 vg)
  • Peripheral organ transduction (liver, heart)
  • Pre-existing neutralizing antibodies can reduce efficacy
  • Dose-dependent liver toxicity

Dosing Considerations: For adult CBS/PSP patients, typical intravenous doses range from 1-3 × 10^14 vg/kg. Pre-treatment screening for anti-AAV neutralizing antibodies is recommended to identify patients who may benefit from alternative delivery routes.

4.2 Direct CNS Delivery

Direct injection into the brain or CSF compartments bypasses the BBB but requires neurosurgical procedures:

Intraparenchymal Injection: Stereotactic injection into specific brain regions enables precise targeting of affected areas (e.g., substantia nigra, basal ganglia for CBS/PSP). This approach reduces required vector doses but provides limited distribution from injection sites[@kaplitt2007].

Intrathecal Delivery: Injection into the cerebrospinal fluid via lumbar puncture enables distribution throughout the brain and spinal cord via CSF circulation. Intrathecal AAV9 administration has been used in clinical trials for spinal muscular atrophy and demonstrates efficient motor neuron transduction.

Intracisternal Injection: Injection into the cisterna magna provides broader CSF distribution than lumbar puncture, with particular relevance for targeting brainstem regions affected in PSP.

flowchart TD
    A["Delivery Routes for CBS/PSP Gene Therapy"]  -->  B["Systemic IV"]

    A  -->  C["Direct CNS"]
    C  -->  C1["Intraparenchymal<br/>Stereotactic"]
    C  -->  C2["Intrathecal<br/>Lumbar Puncture"]
    C  -->  C3["Intracisternal<br/>Cisterna Magna"]

    B  -->  D["BBB Crossing<br/>Required"]
    C1  -->  E["Limited Distribution<br/>Precise Targeting"]
    C2  -->  F["Broad CSF Distribution<br/>Motor Neurons"]
    C3  -->  G["Brainstem Targeting<br/>Cerebellar Access"]

    D  -->  H["High Dose Needed<br/>1-3x10^14 vg/kg"]
    E  -->  I["Low Dose<br/>10^11-10^12 vg"]
    F  -->  J["Moderate Dose<br/>10^13-10^14 vg"]
    G  -->  J

    H  -->  K["Widespread But Variable<br/>CNS Penetration"]
    I  -->  K
    J  -->  K

    style B fill:#0a1929,stroke:#333
    style C fill:#3e2200,stroke:#333
    style K fill:#0a1f0a,stroke:#333

4.3 Enhanced Delivery Strategies

Emerging technologies aim to improve CNS gene therapy delivery:

Focused Ultrasound BBB Opening: MR-guided focused ultrasound (MRgFUS) can temporarily disrupt the BBB, enhancing AAV delivery to specific brain regions. This approach enables reduced vector doses while achieving targeted expression[@aryal2019].

Convection-Enhanced Delivery: Direct intracerebral infusion with positive pressure enables bulk flow distribution, expanding the volume of distribution beyond what occurs with diffusion alone.

Chemical Modification: Conjugation of vectors to brain-targeting molecules (e.g., transferrin receptor antibodies) can enhance BBB crossing while reducing required doses.

5. Target Genes for CBS/PSP

5.1 Tau-Targeting Approaches

Gene therapy for CBS/PSP can directly target tau pathology through multiple mechanisms:

MAPT Gene Silencing: RNA interference (RNAi) or antisense oligonucleotides (ASOs) targeting MAPT mRNA can reduce tau protein production. AAV-delivered shRNA constructs have demonstrated effective tau reduction in preclinical models, with decreased tau pathology and improved behavioral outcomes[@matsumoto2020].

Antisense Oligonucleotides: ASOs can be delivered via AAV (e.g., AAV-ASO) or as gene therapy products. Anti-MAPT ASOs are in clinical development for Alzheimer’s disease, with potential extension to 4R-tauopathies.

Tau Expression Regulation: Genetic approaches can modulate tau expression through targeting transcription factors or regulatory elements controlling MAPT expression.

5.2 Neuroprotective Factors

Gene delivery of neuroprotective proteins can enhance neuronal survival:

GDNF Family: Glial cell line-derived neurotrophic factor (GDNF) and related proteins (neurturin, artemin) promote dopaminergic neuron survival. AAV-GDNF delivery has been explored for Parkinson’s disease with some preclinical success, though clinical translation has faced challenges[@kalia2015].

BDNF: Brain-derived neurotrophic factor supports neuronal survival and synaptic plasticity. AAV-BDNF delivery has shown benefits in tauopathy models but faces challenges with appropriate expression level control.

Neurturin: A GDNF family member with demonstrated safety in Parkinson’s disease clinical trials. May provide trophic support to degenerating neurons in CBS/PSP.

5.3 Anti-Inflammatory Targets

Modulating neuroinflammation through gene therapy addresses a key component of tauopathy pathogenesis:

IL-10 Delivery: Anti-inflammatory interleukin-10 delivery via AAV can shift microglial polarization toward a protective phenotype, reducing pro-inflammatory cytokine production[@shevtsova2020].

CD200/CD200R: The CD200-CD200R immune regulatory axis can be enhanced via gene delivery to suppress microglial activation.

TREM2 Agonists: TREM2 activation on microglia enhances phagocytosis of pathological proteins. TREM2 agonist gene therapy is under development for Alzheimer’s disease with potential relevance to CBS/PSP.

5.4 Protein Homeostasis Enhancement

Enhancing cellular clearance mechanisms can address tau aggregation:

Autophagy Modulation: Gene delivery of autophagy-enhancing proteins (e.g., TFEB, Beclin-1) can promote clearance of tau aggregates through the autophagy-lysosome system[@xiao2019].

Molecular Chaperones: Heat shock proteins (HSP70, HSP90) can be overexpressed to improve tau folding and reduce aggregation. AAV-HSP70 delivery has shown promise in preclinical models.

6. Clinical Development Landscape

6.1 Active and Recent Gene Therapy Trials

Gene therapy for tauopathies remains in early clinical development, with no approved therapies specifically for CBS or PSP. Several programs are advancing through clinical trials:

While these programs focus primarily on Parkinson’s disease, their results inform CBS/PSP development. The ASO approach using IONIS-MAPTRx has demonstrated tau reduction in CSF, supporting the validity of tau-lowering strategies.

6.2 Preclinical Programs in Tauopathies

Multiple preclinical programs specifically target CBS/PSP:

AAV-Anti-Tau shRNA: Multiple academic groups have developed AAV-delivered anti-tau shRNA constructs demonstrating tau reduction and behavioral improvement in tauopathy mouse models. These programs are advancing toward IND-enabling studies.

Tau Vaccine Gene Therapy: AAV-delivered tau immunogens can induce anti-tau antibody production, combining gene therapy with immunotherapy approaches.

Combination Approaches: Programs combining multiple therapeutic mechanisms (e.g., tau silencing + neurotrophic factor expression) are in development.

6.3 Challenges and Future Directions

Patient Selection: Biomarker-driven patient selection will be critical for clinical success. Tau PET, CSF tau measurements, and genetic testing (e.g., MAPT mutations) can identify appropriate patient populations.

Outcome Measures: CBS/PSP clinical trials require sensitive measures of disease progression. Composite scales combining motor and cognitive assessments, alongside biomarker endpoints, will be essential.

Combination Therapies: Gene therapy may be most effective as part of combination approaches addressing multiple disease mechanisms—tau pathology, neuroinflammation, and neuroprotection.

7. Therapeutic Approaches for CBS/PSP

7.1 Current Gene Therapy Options

As of 2026, no FDA-approved gene therapy exists specifically for CBS or PSP. However, several approaches are in development:

Off-label Considerations: While not specifically approved for CBS/PSP, certain gene therapy approaches from Parkinson’s disease programs may be considered for off-label use in clinical settings:

  • AAV-GDNF approaches (where available) may provide neurotrophic support
  • Anti-tau ASOs from Alzheimer’s programs may be considered

7.2 Near-term Opportunities

Clinical Trial Participation: Patients with CBS/PSP should优先考虑 clinical trials of anti-tau therapies, including:

  • ASO programs targeting MAPT
  • Anti-tau immunotherapies
  • Gene therapy programs as they enter clinical development

Monitoring: For patients receiving experimental gene therapy, monitoring should include:

  • Motor and cognitive assessments (MDS-UPDRS, PSP rating scale, CBS assessment)
  • CSF tau species and neurofilament light chain (NfL)
  • Tau PET imaging where available

7.3 Gene Therapy Considerations

When gene therapy becomes available for CBS/PSP, considerations include:

Timing: Earlier intervention may provide greater benefit by preserving neurons before extensive degeneration occurs. However, accurate diagnosis of CBS/PSP can be challenging in early stages.

Delivery Route: Intravenous AAV9 offers broad distribution but requires high doses. Direct CNS delivery may provide more targeted expression with lower doses but requires neurosurgical intervention.

Safety Monitoring: Gene therapy safety monitoring should include:

  • Liver function tests (for systemic delivery)
  • Neurological assessment for immune-mediated effects
  • Anti-vector antibody screening

8. Key Cross-Links

This section connects to the following related topics in NeuroWiki:

9. Summary

Gene therapy vectors, particularly AAV and lentiviral platforms, represent a promising therapeutic approach for CBS and PSP. These 4R-tauopathies are attractive targets for gene therapy due to their well-defined pathological mechanisms, diffuse CNS involvement, and unmet medical need. AAV vectors, especially AAV9, have emerged as the preferred platform due to their demonstrated safety, ability to cross the BBB, and long-term expression characteristics.

Multiple therapeutic strategies are in development, including tau-silencing approaches, neuroprotective factor delivery, anti-inflammatory interventions, and protein homeostasis enhancement. While no gene therapy has reached regulatory approval for CBS/PSP, the field is advancing rapidly, with preclinical programs approaching clinical development and early-phase trials in related indications providing important translational insights.

Successful clinical development will require careful patient selection using tau-focused biomarkers, sensitive outcome measures capturing the multidimensional nature of CBS/PSP, and potentially combination approaches addressing multiple disease mechanisms. As gene therapy technology matures, it holds significant promise for disease modification in these devastating neurodegenerative disorders.

References

  1. Boxer, A. L., et al., (2020). Clinical syndromes associated with progressive supranuclear palsy (2020)
  2. Unknown, Hudry, E., & Kalia, L. V. (2018). Gene therapy for neurodegenerative diseases (2018)
  3. Wang, D., et al, (2019) (2019)
  4. Unknown, Delenda, C., & Savedra, S. (2019). Lentiviral vectors for gene therapy of CNS diseases (2019)
  5. Gray, S. J., et al., (2011). Promoters and regulatory elements for CNS gene therapy (2011)
  6. Unknown, Muzyczka, N., & Srivastava, A. (2022). Adeno-associated virus: A key virus for gene therapy (2022)
  7. Duque, S. I., et al., (2009). Intravenous AAV9 administration mediates widespread CNS transduction (2009)
  8. Deverman, B. E., et al., (2016). Engineered AAV vectors for CNS gene therapy (2016)
  9. Sakuma, T., et al, (2012) (2012)
  10. Foust, K. D., et al., (2013). AAV9-mediated gene delivery to CNS (2013)
  11. Kaplitt, M. G., et al., (2007). Safety and tolerability of AAV2 gene therapy (2007)
  12. Aryal, M., et al, (2019) (2019)
  13. Matsumoto, J., et al, (2020) (2020)
  14. Kalia, L. V., et al., (2015). Gene therapy for Parkinson’s disease (2015)
  15. Shevtsova, Z., et al, (2020) (2020)
  16. Xiao, Q., et al, (2019) (2019)

See Also

Related Hypotheses:

Related Analyses:

Related Experiments: